ZYKR 1
Alternative Names: ZYKR-1Latest Information Update: 28 Sep 2022
At a glance
- Originator Cadila Healthcare
- Developer Zydus Lifesciences
- Class Analgesics; Peptides
- Mechanism of Action Opioid kappa receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Postoperative pain; Visceral pain
Most Recent Events
- 28 Sep 2022 No recent reports of development identified for phase-I development in Visceral-pain(In volunteers) in India (IV, Infusion)
- 28 Sep 2021 No recent reports of development identified for phase-I development in Postoperative-pain(In volunteers) in India (IV, Infusion)
- 23 Jun 2020 Cadila Healthcare discontinues a phase I trial for Visceral pain and Postoperative pain (In volunteers) in India, before June 2020 (IV) (CTRI2018-07-014927)